Download PDF
Semin Thromb Hemost 2005; 31(1): 17-24
DOI: 10.1055/s-2005-863801
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Antiphospholipid Syndrome: Clinical and Diagnostic Utility of Laboratory Tests

Monica Galli1 , 2 , Tiziano Barbui2
  • 1Assistant Professor, Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
  • 2Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
Further Information

Publication History

Publication Date:
11 February 2005 (online)

    Permissions and Reprints

ABSTRACT

Antiphospholipid antibodies are a wide and heterogeneous group of immunoglobulins that include, among others, lupus anticoagulants and anticardiolipin antibodies. Their presence in patients with arterial and venous thrombosis, and/or obstetrical complications, defines the antiphospholipid syndrome. Antiphospholipid antibodies do not recognize anionic phospholipids, but recognize plasma proteins bound to suitable anionic surfaces: β2-glycoprotein I and prothrombin are the most common and most frequently investigated antigens. We systematically reviewed published articles on the antiphospholipid syndrome to investigate the association between thrombosis and some antiphospholipid antibodies. Lupus anticoagulants were a clear risk factor for thrombosis, irrespective of the site and type of thrombosis, the presence of systemic lupus erythematosus, and the methods used to detect them. Anticardiolipin and anti-β2-glycoprotein I antibodies were possible risk factors of thrombosis, at least in some selected situations. The measurement of antiprothrombin antibodies is not helpful to define the patient's risk of thrombosis. These results are mainly due to the still far from optimal standardization of the methods to detect antiphospholipid antibodies; the lack of standardized reference materials; the heterogeneity in reagents, calibrators, and assay conditions; and the methods used to calculate the results. Many efforts are currently being made to improve assay standardization and harmonization, which should help to clarify the clinical relevance of antiphospholipid antibodies.

KEYWORDS

Antiphospholipid syndrome - antiphospholipid antibodies - lupus anticoagulants - thrombosis

REFERENCES

  • 1 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome.  Arthritis Rheum. 1999;  42 1309-1311
    CrossrefPubMedGoogle Scholar
  • 2 Asherson R A, Khamashta M A, Ordi-Ros J et al.. The “primary” antiphospholipid syndrome; major clinical and serological features.  Medicine (Baltimore). 1989;  68 366-374
    PubMedGoogle Scholar
  • 3 Alarcon-Segovia D, Deleze M, Oria C V, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients.  Medicine (Baltimore). 1989;  68 353-365
    PubMedGoogle Scholar
  • 4 Triplett D A, Boffa M C. Lupus anticoagulant: detection, standardization and heterogeneity. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y The Antiphospholipid Syndrome II. Autoimmune Thrombosis. Amsterdam; Elsevier 2002: 23-28
    Google Scholar
  • 5 Pierangeli S S, Harris E N. Antibodies to cardiolipin and other phospholipids. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y The Antiphospholipid Syndrome II. Autoimmune Thrombosis. Amsterdam; Elsevier 2002: 29-43
    Google Scholar
  • 6 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.  Thromb Haemost. 1995;  74 1185-1190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Galli M, Comfurius P, Maassen C et al.. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
    CrossrefPubMedGoogle Scholar
  • 8 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci USA. 1990;  87 4120-4127
    CrossrefPubMedGoogle Scholar
  • 9 Matsuura E, Igarashi Y, Fujimoto M et al.. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.  Lancet. 1990;  336 177-178
    PubMedGoogle Scholar
  • 10 Bevers E M, Galli M, Barbui T, Comfurius P, Zwaal RF A. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.  Thromb Haemost. 1991;  66 629-632
    PubMedGoogle Scholar
  • 11 Galli M, Comfurius P, Barbui T, Zwaal RF A, Bevers E M. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies.  Thromb Haemost. 1992;  68 297-300
    PubMedGoogle Scholar
  • 12 Galli M, Beretta G, Daldossi M, Bevers E M, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies.  Thromb Haemost. 1997;  77 486-491
    PubMedGoogle Scholar
  • 13 Willems G M, Janssen M P, Pelsers M M et al.. Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-glycoprotein I complexes to lipid membranes.  Biochemistry. 1996;  35 13833-13842
    CrossrefPubMedGoogle Scholar
  • 14 Willems G M, Janssen M P, Comfurius P et al.. Kinetics of prothrombin-mediated binding of lupus anticoagulant antibodies to phosphatidylserine-containing phospholipid membranes: an ellipsometric study.  Biochemistry. 2002;  41 14357-14363
    CrossrefPubMedGoogle Scholar
  • 15 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta-2-glycoprotein I complexes on phospholipid surfaces.  Thromb Haemost. 1998;  79 79-86
    PubMedGoogle Scholar
  • 16 Field S L, Chesterman C N, Dai Y P, Hogg P J. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid.  J Immunol. 2001;  166 6118-6125
    PubMedGoogle Scholar
  • 17 Shi W, Chong B H, Hogg P J et al.. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity.  Thromb Haemost. 1993;  70 342-345
    PubMedGoogle Scholar
  • 18 Permpkul P, Rao LV M, Rapaport S I. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity.  Blood. 1994;  83 2878-2892
    PubMedGoogle Scholar
  • 19 Horbach D A, van Oort E, Derksen R HWM et al.. The contribution of anti-prothrombin antibodies to lupus anticoagulant activity: discrimination between functional and non-functional anti-prothrombin antibodies.  Thromb Haemost. 1998;  79 790-795
    PubMedGoogle Scholar
  • 20 Simmelink M JA, Derksen R HWM, Arnout J, de Groot P G. A simple method to discriminate between β2-glycoprotein I- and prothrombin-dependent lupus anticoagulants.  J Thromb Haemost. 2003;  1 740-747
    CrossrefPubMedGoogle Scholar
  • 21 Greaves M, Cohen H, Machin S I, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome.  Br J Haematol. 2000;  109 704-715
    CrossrefPubMedGoogle Scholar
  • 22 Roussi J, Roisin J P, Goguel A. Lupus anticoagulants. First French interlaboratory etalanorme survey.  Am J Clin Pathol. 1996;  105 788-793
    PubMedGoogle Scholar
  • 23 Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants.  Thromb Haemost. 2001;  86 83-91
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Jennings I, Kitchen S, Woods TA L, Preston F E, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK national external quality assessment scheme (NEQAS) for blood coagulation.  Thromb Haemost. 1997;  77 934-937
    PubMedGoogle Scholar
  • 25 Jennings I, Greaves M, Mackie I J, Kitchen S, Woods TA L, Preston F E. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods.  Br J Haematol. 2002;  119 364-369
    CrossrefPubMedGoogle Scholar
  • 26 Le Querrec A, Arnout J, Arnoux D et al.. Quantification of lupus anticoagulants in clinical samples using anti-β2-glycoprotein I and anti-prothrombin monoclonal antibodies.  Thromb Haemost. 2001;  86 584-589
    PubMedGoogle Scholar
  • 27 Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European concerted action of thrombophilia (ECAT) survey using plasma spiked with monoclonal antibodies against human β2-glycoprotein I.  Thromb Haemost. 1999;  81 929-934
    PubMedGoogle Scholar
  • 28 Reber G, Arvieux J, Comby E et al.. Multicenter evaluation of nine commercial kits for the quantification of anticardiolipin antibodies.  Thromb Haemost. 1995;  73 444-452
    PubMedGoogle Scholar
  • 29 Harris E N, Gharavi A E, Patel S, Hughes GR V. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held April 4 1986.  Clin Exp Immunol. 1987;  68 215-222
    PubMedGoogle Scholar
  • 30 Harris E N. The second international anticardiolipin standardization workshop/the Kingston Antiphospholipid Antibody study (KAPS) group.  Am J Clin Pathol. 1990;  94 476-484
    PubMedGoogle Scholar
  • 31 Harris E N, Pierangeli S, Birch D. Anticardiolipin wet workshop: 5th International Symposium on antiphospholipid antibodies.  Am J Clin Pathol. 1994;  101 616-624
    PubMedGoogle Scholar
  • 32 Pierangeli S S, Stewart M, Silva L K, Harris E N. Report of an anticardiolipin wet workshop during the VIIth International Symposium on antiphospholipid antibodies.  J Rheumatol. 1998;  25 156-162
    PubMedGoogle Scholar
  • 33 Tincani A, Allegri F, Sanmarco M et al.. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European Antiphospholipid Forum.  Thromb Haemost. 2001;  86 575-583
    PubMedGoogle Scholar
  • 34 Favaloro E J, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays.  Am J Clin Pathol. 2002;  118 548-557
    CrossrefPubMedGoogle Scholar
  • 35 Reber G, Schousboe I, Tincani A et al.. Inter-laboratory variability of anti-β2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on antiphospholipid antibodies standardization group.  Thromb Haemost. 2002;  88 66-73
    PubMedGoogle Scholar
  • 36 Donohoe S, Mackie J I, Isenberg D, Machin S J. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome.  Br J Haematol. 2001;  113 544-549
    CrossrefPubMedGoogle Scholar
  • 37 Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infection.  Clin Immunol Immunopathol. 1986;  41 8-15
    CrossrefPubMedGoogle Scholar
  • 38 Sammaritano L R. Drug-induced antiphospholipid antibodies. In: Khamashta MA Hughes Syndrome. The Antiphospholipid Syndrome London; Springer 2000: 144-154
    Google Scholar
  • 39 Asherson R A. Antiphospholipid antibodies, malignancies and paraproteinemias.  J Autoimmun. 2000;  15 117-122
    CrossrefPubMedGoogle Scholar
  • 40 Santiago M, Martinelli R, Ko A et al.. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar.  Clin Exp Rheumatol. 2001;  19 425-430
    PubMedGoogle Scholar
  • 41 Guerin J, Smith O, White B, Sweetman G, Feighery C, Jackson J. Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders.  Br J Haematol. 1998;  102 896-902
    CrossrefPubMedGoogle Scholar
  • 42 Giordano P, Galli M, Del Vecchio G et al.. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassemia.  Br J Haematol. 1998;  102 903-906
    CrossrefPubMedGoogle Scholar
  • 43 El-roey A, Gleicher N. Definition of normal autoantibody levels in apparently healthy population.  Obstet Gynecol. 1988;  72 596-602
    PubMedGoogle Scholar
  • 44 Vila P, Hernandez M C, Lopez-Fernandez M F, Batle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects.  Thromb Haemost. 1994;  72 209-213
    PubMedGoogle Scholar
  • 45 Manoussakis M N, Tzioufas A G, Silis M P et al.. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population.  Clin Exp Immunol. 1987;  69 557-565
    PubMedGoogle Scholar
  • 46 Fields R A, Toubbeh H, Searles R P, Bankhurst A D. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies.  J Rheumatol. 1989;  16 623-625
    PubMedGoogle Scholar
  • 47 Shi W, Krilis S A, Chong B H, Gordon S, Chesterman C N. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.  Aust N Z J Med. 1990;  20 231-236
    PubMedGoogle Scholar
  • 48 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.  Blood. 2003;  101 1827-1832
    CrossrefPubMedGoogle Scholar
  • 49 Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile.  Thromb Haemost. 1999;  81 695-700
    PubMedGoogle Scholar
  • 50 Galli M, Dlott J, Norbis F et al.. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.  Thromb Haemost. 2000;  84 1012-1016
    PubMedGoogle Scholar
  • 51 Forastiero R R, Martinuzzo M E, Cerrato G S, Kordich L C, Carreras L O. Relationship of antiß2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies.  Thromb Haemost. 1997;  78 1008-1014
    PubMedGoogle Scholar
  • 52 Simmelink MJ A, Horbach D A, van Oort E, Derksen R HWM, de Groot P G. DRVVT is a much better predictor than KCT for the risk of thrombosis.  Lupus. 1998;  7(suppl 2) S219
    PubMedGoogle Scholar
  • 53 Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome.  Blood. 2003;  102 2717-2723
    CrossrefPubMedGoogle Scholar
  • 54 Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and anti-prothrombin antibodies on the anticoagulant activity of activated protein C.  Blood. 1998;  91 1999-2004
    PubMedGoogle Scholar
  • 55 Field S L, Chesterman C N, Hogg P J. Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies.  Thromb Haemost. 2000;  84 1132-1133
    PubMedGoogle Scholar

Monica GalliM.D. Ph.D. 

Divisione di Ematologia, Ospedali Riuniti, L.go Barozzi

1, 24128 Bergamo, Italy

Email: monicagalli@virgilio.it